| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Actuate Therapeutics, Inc.$1.21
0 (0%)
D 26Pipeline Score Richly Valued Pharma · Clinical
Market Cap
56.94 M
EPS
-0.99
P/E Ratio
-
Value Trade
152.17 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.57 M
Operating CF
-5.02 M
Total Assets
8.91 M
Total Liabilities
5.13 M
Equity
3.78 M
D/E Ratio
12,345
-17.36 %
Week
0 %
1 Month
-43.6 %
3 Month
-60.86 %
6 Month
-75.91 %
5 Year
-75.91 %
All Time
Cash Data
Cash Position
8.13 M
Monthly Burn
1.67 M
Runway
3.2 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
255.68 K
52 Week Range
1.58 - 11.99
% held by Insiders
56.99 %
% held by Institutions
15.98 %
Enterprise Value
49.21 M
Total Shares
23.68 M
Short %
8.9 %
Float Shares
9.54 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Actuate Therapeutics, Inc.
100Total events
3Upcoming
19Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 3
Event history 97
Q3 2026
◆Trial InitiationelraglusibTrial
Initiation of Phase 1/2 study of oral elraglusib planned for 2H 2026
advanced solid tumors (melanoma, NSCLC, colorectal, pancreatic)source ↗
Jun 9, 2026
▲Trial InitiationelraglusibTrial
Elraglusib selected for evaluation in BEACON2 trial
high-risk pediatric neuroblastomasource ↗
Jun 1, 2026
▲Poster PresentationelraglusibPresentation
Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel vs chemotherapy alone in mPDAC presented at ASCO 2026
metastatic pancreatic ductal adenocarcinomasource ↗
May 11, 2026
▲IND ClearanceelraglusibIND
FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients
advanced solid tumorssource ↗
May 11, 2026
◆FDA Feedback ReceivedelraglusibFDA Meeting
EMA provided guidance on trial design for potential single registration study for IV treatment of mPDAC
metastatic pancreatic ductal adenocarcinoma (mPDAC)source ↗
May 6, 2026
Apr 14, 2026
▲PublicationelraglusibPresentation
Nature Medicine publication of Phase 2 trial results for elraglusib plus GnP in metastatic pancreatic cancer
metastatic pancreatic ductal adenocarcinomasource ↗
Q2 2026
◆Trial InitiationelraglusibTrial
Initiation of phase 1 portion of elraglusib tablet trial planned in 2H 2026
advanced cancersource ↗
Q2 2026
◆Preclinical PoCelraglusibPreclinical
Preclinical results of elraglusib plus RAS inhibitor expected in mid-2026
RAS-driven cancerssource ↗
Mar 10, 2026
◆Oral PresentationPresentation
Actuate Therapeutics to present at Citizens Life Sciences Conference
Mar 9, 2026
●Preclinical PoCelraglusibPreclinical
Launch of strategic research initiative combining elraglusib with RAS inhibitors
RAS-driven cancerssource ↗
Drug Pipeline Intelligence
D26
Pipeline Score $5M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 27%
Micro Cap (rank 666 of 911)
Percentile RankActuate Therapeutics, Inc. faces pipeline headwinds (26/100), with $243M risk-adjusted pipeline value, led by 9-ING-41 in Cancer (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9-ING-41 Small molecule | Cancer | Phase 2 | NCT03678883 | 10% | $134M | ACTIVE NOT_RECRUITING | 350 | FAST | C (53) | Jun 1, 2026 | ELEVATED_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
elraglusib OrphanRare Pediatric | high-risk pediatric neuroblastoma | Phase 1/2 | 2026-06-09 | Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers; 60% of Th-MYCN mice treated with elraglusib plus temozolomide/irinotecan (TEMIRI)/14G2a, remained tumor-free at one year of age compared to 0% in the TEMIRI/14G2a only arm (P<0.0001) Read More | Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma Read More | |
elraglusib OrphanRare Pediatric | high-risk pediatric neuroblastoma | Phase 1/2 | 2026-06-09 | Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers; 60% of Th-MYCN mice treated with elraglusib plus temozolomide/irinotecan (TEMIRI)/14G2a, remained tumor-free at one year of age compared to 0% in the TEMIRI/14G2a only arm (P<0.0001) Read More | Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma Read More | |
elraglusib OrphanRare Pediatric | high-risk pediatric neuroblastoma | Phase 1/2 | 2026-06-09 | Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers; 60% of Th-MYCN mice treated with elraglusib plus temozolomide/irinotecan (TEMIRI)/14G2a, remained tumor-free at one year of age compared to 0% in the TEMIRI/14G2a only arm (P<0.0001) Read More | Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACTU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACTU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACTU▲ +10.4%on this news
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Actuate Therapeutics announced that elraglusib will be evaluated in the BEACON2 trial, targeting high-risk pediatric neuroblastoma. This Phase 1/2 trial will assess elraglusib in combination with dinutuximab beta and chemotherapy. The trial aims to confirm safety and establish dosing parameters, following promising results from earlier studies.
Read more →ACTUActuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Actuate Therapeutics announced promising results from two studies presented at the 2026 ASCO Annual Meeting, highlighting the effectiveness of elraglusib in first-line treatment for metastatic pancreatic cancer. The data showed significant improvements in median overall survival for patients with KRAS and P53 wild-type genomics when elraglusib was used with established chemotherapy regimens like gemcitabine/Abraxane and FOLFIRINOX. The treatment was well tolerated, demonstrating a favorable safety profile. These findings suggest that elraglusib may serve as a differentiated therapy and contribute to improving outcomes in challenging cancer cases.
Read more →ACTU2026-ASCO-Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma
The article provides information about a post-hoc efficacy and biomarker analysis of elraglusib combined with gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma. However, the content does not present specific results or conclusions from the analysis, focusing instead on website cookie policies.
Read more →ACTU2026-ASCO-A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
The article discusses a phase II study presented at 2026-ASCO-A, which investigates the efficacy of a combination therapy involving FOLFIRINOX, elraglusib, and losartan in patients with untreated metastatic pancreatic ductal adenocarcinoma. This research aims to assess the potential benefits of these agents in improving treatment outcomes for this challenging cancer type.
Read more →ACTU▼ -9.8%on this news
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Actuate Therapeutics has received FDA clearance for an Investigational New Drug application for its oral formulation of elraglusib, aimed at treating advanced cancers. The Phase 1/2 study will focus on patients with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, with initiation planned for the second half of 2026. The company is also exploring combination therapies with RAS inhibitors and has welcomed a new board member to enhance its strategic capabilities.
Read more →ACTUActuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies
Actuate Therapeutics has appointed Martin Huber, MD, as an Independent Director to its Board of Directors, effective immediately. Dr. Huber brings significant experience in oncology drug development, having previously held leadership roles at Mersana Therapeutics, Xilio Therapeutics, and TESARO. This strategic appointment is expected to strengthen Actuate's efforts in advancing their lead investigational drug, elraglusib, through various cancer indications. Elraglusib specifically targets a well-established pathway that may improve outcomes for patients with difficult-to-treat cancers.
Read more →ACTU▲ +14.3%on this news· ran to +27% by day 3
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
The article discusses a randomized controlled phase 2 trial investigating the combination of Elraglusib and chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. The trial aims to evaluate the efficacy and safety of this treatment approach. However, detailed results and findings from the trial are not provided in the text.
Read more →ACTU▲ +14.3%on this news· ran to +27% by day 3shared move
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Actuate Therapeutics announced promising results from a Phase 2 clinical trial of elraglusib combined with chemotherapy for metastatic pancreatic cancer. The study demonstrated a 40% increase in median overall survival and a one-year survival rate of 44% compared to 22% with standard treatment. The findings suggest elraglusib's potential as a first-line therapy, especially in high-risk patient groups.
Read more →ACTU▼ -15.3%on this news
2026-AACR-Inhibition of GSK3B signaling in pediatric brain tumors
The article discusses the use of cookies on a website, focusing on user consent and functionality. It outlines the types of cookies used, including necessary, functional, and analytical cookies, and emphasizes the importance of user consent for data collection. However, it does not provide specific information regarding the inhibition of GSK3B signaling in pediatric brain tumors.
Read more →ACTUActuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Actuate Therapeutics has launched a strategic research initiative to evaluate the combination of its GSK-3β inhibitor elraglusib with RAS-targeted therapies. This initiative aims to enhance treatment efficacy for difficult-to-treat cancers, particularly pancreatic cancer. Initial preclinical results are anticipated in the second half of 2026, with the potential to improve clinical outcomes in RAS-driven cancers.
Read more →ACTUActuate Therapeutics to Present at The Citizens Life Sciences Conference
Actuate Therapeutics, a clinical-stage biopharmaceutical company, will present at the Citizens Life Sciences Conference on March 10, 2026. CEO Dan Schmitt will discuss the company's focus on therapies for difficult-to-treat cancers, particularly their lead drug, elraglusib. The presentation will be available via webcast, and the management team will hold one-on-one meetings with attendees.
Read more →ACTUTherapeutic targeting of epithelial-mesenchymal cellular plasticity in pancreatic cancer
The article discusses the therapeutic targeting of epithelial-mesenchymal cellular plasticity in pancreatic cancer. It emphasizes the importance of understanding cellular behavior in cancer treatment. However, the article lacks specific details or findings related to this topic.
Read more →ACTU▲ +10.6%on this news
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Actuate Therapeutics will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Dan Schmitt will discuss the company's focus on therapies for challenging cancers, particularly their lead drug, elraglusib. The presentation will be available via webcast, and one-on-one meetings with investors are scheduled during the event.
Read more →ACTU▼ -7%on this news
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Actuate Therapeutics announced plans to initiate a Phase 1/2 clinical program for elraglusib, an oral tablet aimed at treating refractory cancers. The Phase 1 trial will focus on determining the maximum tolerated dose and assessing preliminary anti-tumor activity. The Phase 2 portion will target specific indications, including refractory melanoma, building on previous encouraging results. The company aims to explore additional cancer indications with this formulation.
Read more →ACTUActuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
Actuate Therapeutics has reported promising follow-up data from its Phase 2 trial of elraglusib combined with chemotherapy for metastatic pancreatic cancer. The study indicates that this combination may significantly improve overall survival compared to standard chemotherapy alone. The findings were presented at the ASCO GI 2026, highlighting the potential of elraglusib in addressing the high unmet medical need in this patient population.
Read more →ACTU▲ +5%on this news
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Actuate Therapeutics announced positive outcomes from its Phase 1 trial of elraglusib in pediatric cancers, showcasing significant clinical responses in patients with refractory Ewing sarcoma and neuroblastoma. Specifically, two complete metabolic responses and one complete response were observed among the participants. The results support the potential of elraglusib, both as a monotherapy and in combination therapies, leading to further clinical development plans scheduled for 2026. The company has also received Rare Pediatric Designations from the FDA for these indications.
Read more →ACTUActuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
Actuate Therapeutics announced that data from its Phase 2 study of elraglusib in metastatic pancreatic cancer will be presented at the ASCO GI Cancers Symposium in January 2026. The study investigates elraglusib in combination with gemcitabine/nab-paclitaxel, a first-line chemotherapy regimen. This acknowledgment at a prestigious conference highlights the importance and potential of the treatment in addressing a critical health issue. Additionally, Actuate aims to explore mutational analyses and biomarkers associated with treatment outcomes.
Read more →ACTU▼ -8.8%on this newsshared move
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics has published positive Phase II clinical data for elraglusib, a GSK-3β inhibitor, combined with platinum chemotherapy in patients with recurrent, metastatic salivary gland carcinoma. The study showed a median overall survival of 18.6 months and identified nuclear GSK-3β expression as a potential biomarker for treatment response. These findings could pave the way for future clinical studies in this challenging cancer type.
Read more →ACTUPotential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL)
The article discusses the potential therapeutic effects of GSK-3β inhibitor 9-ING-41 in combination with venetoclax for treating double-hit lymphoma (DHL). However, the article lacks specific details about the study results or implications of this combination therapy.
Read more →ACTU2025-AACR-NCI-EORTC-The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model
The article discusses the glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy. It highlights the potential for long-term survival in the Th-MYCN mouse model. However, specific details about the study's findings or implications are not provided.
Read more →ACTU▲ +15.4%on this news
Elraglusib, a glycogen synthase kinase-3β (GSK-3β) inhibitor, plus chemotherapy with or without immunotherapy in patients with recurrent, metastatic salivary gland carcinoma.
The article discusses the use of Elraglusib, a GSK-3β inhibitor, in combination with chemotherapy and potentially immunotherapy for patients suffering from recurrent, metastatic salivary gland carcinoma. However, the article does not provide specific details on clinical outcomes or study results. It primarily focuses on the treatment approach without delving into patient responses or efficacy data.
Read more →ACTU▲ +6.8%on this news
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Actuate Therapeutics has updated its IND application with new clinical data supporting elraglusib for metastatic pancreatic cancer. The Phase 2 trial demonstrated significant improvements in overall survival with elraglusib combined with chemotherapy. The company is preparing for regulatory submissions to the FDA and EMA, bolstered by a recent financing round. However, challenges remain regarding regulatory approval and potential side effects.
Read more →ACTUActuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
Actuate Therapeutics has successfully closed a $17.25 million public offering of common stock, including the full exercise of an over-allotment option. The offering consisted of 2,464,286 shares priced at $7.00 each. The proceeds will be used for working capital and general corporate purposes. Lucid Capital Markets acted as the sole book-running manager for the offering.
Read more →ACTU▼ -19.2%on this newsshared move
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
Actuate Therapeutics has announced the pricing of a public offering of 2,142,858 shares at $7.00 per share, aiming to raise approximately $15 million. The offering is set to close on September 11, 2025, and will be used for working capital and corporate purposes. Lucid Capital Markets is the sole book-running manager for this offering.
Read more →ACTU▼ -19.2%on this newsshared move
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
Actuate Therapeutics, Inc. has announced a proposed public offering of its common stock to raise funds for working capital and corporate purposes. The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. The company is focused on developing therapies for challenging cancers, but the offering's completion is subject to market conditions.
Read more →ACTUApoE4 upregulates GSK-3β to aggravate Alzheimer-like pathologies and cognitive impairment in type 2 diabetic mice
The article discusses the role of ApoE4 in exacerbating Alzheimer-like symptoms and cognitive decline in type 2 diabetic mice, focusing on its upregulation of GSK-3β. This research highlights the potential link between diabetes and Alzheimer's pathology, suggesting that ApoE4 may play a significant role in these conditions. The findings could lead to further investigations into therapeutic strategies targeting GSK-3β.
Read more →ACTU▲ +11.8%on this news
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
Actuate Therapeutics has launched a Phase 1b trial for elraglusib combined with retifanlimab and mFOLFIRINOX in patients with advanced pancreatic adenocarcinoma. This trial aims to determine the recommended phase 2 dose while evaluating efficacy and safety. The study is conducted in collaboration with Incyte Corporation and UPMC Hillman Cancer Center, building on promising preclinical data.
Read more →ACTUActuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
Actuate Therapeutics has completed a Phase 1 study of elraglusib, showing promising results in pediatric patients with refractory Ewing Sarcoma. Two patients achieved complete responses, while two others had stable disease. The company plans to advance to a Phase 2 trial, aiming to address the significant treatment gaps in this aggressive cancer.
Read more →ACTUActuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
Actuate Therapeutics reported promising results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. The treatment demonstrated a near doubling of 1-year overall survival and a 43% reduction in risk of death compared to the control group. Notably, patients with liver metastases showed a 2.5-fold increase in 1-year survival. These findings suggest significant potential for elraglusib in high-risk patient populations.
Read more →ACTUActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Actuate Therapeutics reported promising biomarker data from its Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. The study identified several biomarkers, particularly CXCL2, that predict overall survival and suggest elraglusib's potential to positively influence the immune microenvironment. The company plans to further explore these biomarkers in future trials.
Read more →ACTUActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Actuate Therapeutics announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025. This milestone follows positive Phase 2 trial results for its lead candidate, elraglusib, which demonstrated a significant increase in median overall survival. The inclusion is expected to enhance the company's visibility and support its growth strategy.
Read more →ACTUTranscript of Key Opinion Leader Event Event Details Date: 2025-05-31 Company: Actuate Therapeutics, Inc. Ticker: ACTU-US Link to access replay: https://lifescievents.com/event/actuate/ Company Participants Daniel Schmit
Actuate Therapeutics, Inc. hosted a Key Opinion Leader event focusing on their Phase 2 study of elraglusib in first-line treatment for metastatic pancreatic cancer. The session featured insights from leading oncologists, including data that highlights elraglusib's promising effects on immune response. Experts emphasized the drug's potential to target various components of pancreatic tumors, suggesting an innovative approach to treatment. The event showcased a blend of clinical insights and initial study results, indicating a hopeful outlook for the drug's future use in oncology.
Read more →ACTU▼ -11%on this news· ran to -24% by day 3shared move
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Actuate Therapeutics announced positive topline results from its Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. The study demonstrated a median overall survival increase of 10.1 months, significantly improving patient outcomes. Key Opinion Leaders discussed the implications of these results, emphasizing the need for innovative treatments in this challenging area.
Read more →ACTU▼ -11%on this news· ran to -24% by day 3shared move
Corporate Overview
The corporate overview for ACTU highlights the company's forward-looking statements regarding its clinical trials and operational plans. It notes that while elraglusib shows potential clinical benefit in various cancers, there are significant financial risks, including ongoing operating losses and reliance on obtaining additional capital. The presentation emphasizes the uncertainties inherent in the drug development process. Additionally, it identifies competitive pressures and regulatory challenges that could impact the company's future success.
Read more →ACTU▼ -11%on this news· ran to -24% by day 3shared move
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Actuate Therapeutics presented positive results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer at the ASCO Annual Meeting. The trial demonstrated a significant improvement in median overall survival, increasing from 7.2 months to 10.1 months, with a notable reduction in the risk of death. Additionally, the combination therapy doubled the 12-month survival rate compared to chemotherapy alone. The company plans to engage with health authorities to discuss a pathway toward potential product registration.
Read more →ACTU2025-ASCO-Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 38) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment
The article discusses a phase 2 trial evaluating elraglusib, a GSK-3 inhibitor, in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma. It highlights the use of machine learning to predict overall survival based on pre-dose plasma biomarkers, aiming to improve patient enrichment strategies. This innovative approach could enhance treatment outcomes.
Read more →ACTU▼ -8%on this newsshared move
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Actuate Therapeutics announced that the Phase 2 trial results of elraglusib, in combination with gemcitabine/nab-paclitaxel, demonstrated statistically significant improvements in median overall survival and 1-year survival rates for patients with metastatic pancreatic ductal adenocarcinoma. The results will be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. The company's CEO emphasized the potential of elraglusib as a promising treatment option, highlighting its clinical activity and commercial prospects.
Read more →ACTUPhase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer
The article discusses a Phase II study involving elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine and nab-paclitaxel for treating previously untreated metastatic pancreatic cancer. However, the article does not provide specific details or results from the study, focusing instead on website cookie policies.
Read more →ACTUActuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
Actuate Therapeutics is set to host a key opinion leader event during the 2025 ASCO annual meeting, where it will present topline Phase 2 data for elraglusib in patients with metastatic pancreatic ductal adenocarcinoma. The event, scheduled for May 31, 2025, will feature insights from leading oncologists on the clinical relevance of the study's findings. This presents an opportunity for the company to discuss potential impacts on treatment paradigms for this aggressive cancer type. The data presentation will include both oral and poster sessions highlighting the study's outcomes and biomarker-driven prediction models.
Read more →ACTU▼ -6.9%on this newsshared move
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - Topline data shows statistically significant impr
Actuate Therapeutics announced positive topline results from its Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic cancer. This trial demonstrated a statistically significant improvement in median overall survival compared to prior data. The planned presentation at the American Society of Clinical Oncology (ASCO) meeting aims to share these results and outline the next steps for the regulatory process. The company is optimistic about advancing elraglusib towards New Drug Application (NDA) based on the trial outcomes.
Read more →ACTUActuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
Actuate Therapeutics announced that its CEO, Daniel Schmitt, will present at the Citizens Life Sciences Conference 2025 on May 8 in New York. The presentation will focus on the company's investigational drug elraglusib, which targets difficult-to-treat cancers through the inhibition of GSK-3β. The management team will also engage in one-on-one meetings with investors during the conference. Actuate emphasizes its commitment to developing transformative therapies in an evolving biopharmaceutical landscape.
Read more →ACTU▲ +5.6%on this news
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Actuate Therapeutics has announced that topline data from its Phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel will be presented at the ASCO Annual Meeting in 2025. The study, focusing on previously untreated metastatic pancreatic ductal adenocarcinoma, highlights the potential of elraglusib as a treatment option. The data presentation will take place on May 31, 2025, underscoring Actuate's commitment to developing therapies for challenging cancer types. However, the company also faces several risks related to trial outcomes and financial sustainability.
Read more →ACTUActuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
Actuate Therapeutics is scheduled to present data on elraglusib as a treatment for advanced salivary gland carcinoma at the AACR Annual Meeting 2025. The presentation will include findings from a study that shows promising response rates among patients, especially in those with nuclear GSK-3β overexpression. Additionally, another research group will discuss the potential synergistic effects of elraglusib combined with other investigational drugs. However, the press release emphasizes the inherent risks and uncertainties associated with drug development processes.
Read more →ACTUPerturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
The article discusses the impact of perturbing LSD1 and WNT pathways on transcription, which may lead to enhanced differentiation in acute myeloid leukemia (AML). The findings suggest a potential therapeutic strategy for AML by targeting these pathways. However, specific details on results or implications are not provided in the text.
Read more →ACTU2025-AACR-Elraglusib, a glycogen synthase kinase-3β (GSK-3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancer
The article discusses the use of Elraglusib, a GSK-3β inhibitor, in combination with chemotherapy and potentially immunotherapy for treating advanced salivary gland cancer. It highlights the ongoing research and potential benefits of this treatment approach. However, specific results or conclusions from studies are not provided in the text.
Read more →ACTUActuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
Actuate Therapeutics has completed enrollment for a Phase 2 trial assessing the combination of elraglusib, FOLFIRINOX, and losartan in previously untreated patients with metastatic pancreatic adenocarcinoma. Initial data from the trial, presented at a conference, indicated early evidence of enhanced clinical activity. The trial involves 56 patients and aims to evaluate safety, tolerability, and progression-free survival. Final results from the study are expected in 2026, highlighting the ongoing commitment of Actuate to improve treatment options for difficult-to-treat cancers.
Read more →ACTU▼ -6.6%on this news
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
Actuate Therapeutics, Inc. has announced its participation in two upcoming investor conferences in February 2025, including the BIO CEO & Investor Conference and the B. Riley Precision Oncology & Radiopharma Conference. CEO Daniel Schmitt will represent the company and engage in one-on-one meetings with registered investors. Actuate is focused on developing therapies for challenging cancers, with its lead drug candidate elraglusib showing promise as a GSK-3β inhibitor. However, the company acknowledges significant risks associated with clinical and regulatory pathways in its development process.
Read more →ACTUActuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Actuate Therapeutics has announced that the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation for elraglusib, a GSK-3β inhibitor, aimed at treating pancreatic ductal adenocarcinoma (PDAC). This designation highlights the critical need for new therapies in addressing such aggressive forms of cancer with limited options. Recent positive interim data from a Phase 2 trial of elraglusib show promising anti-tumor activity and improved survival rates compared to standard treatment. The company aims to advance elraglusib’s clinical development and reports topline data in the first half of 2025.
Read more →ACTU▼ -11.9%on this news· ran to -22% by day 3
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Over
Actuate Therapeutics announced encouraging interim results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel for treating metastatic pancreatic cancer. The data showed a statistically significant improvement in both the 1-year survival rate and median overall survival compared to the control group. Additionally, patients in the elraglusib-GnP combination group exhibited complete and partial responses, highlighting the potential of this combination therapy. The trial continues, with topline data expected in the first half of 2025, pointing to further developments in this innovative treatment approach.
Read more →ACTUActuate Therapeutics to be Added to Russell 2000 Index
Actuate Therapeutics, Inc. announced its upcoming inclusion in the Russell 2000 Index, effective December 23, 2024. This development positions the company for greater market visibility and potential investment opportunities. Actuate focuses on therapies for challenging cancers, with its lead candidate, elraglusib, aiming to enhance anti-tumor immunity. Nonetheless, the company faces significant clinical development risks, including potential safety issues and the uncertainty of regulatory approvals.
Read more →ACTUActuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumr in
Actuate Therapeutics has received Rare Pediatric Disease Designation from the FDA for elraglusib, a novel GSK-3 inhibitor intended for treating Ewing sarcoma. This designation highlights the urgent need for effective treatments in this serious condition. The ongoing Phase 1/2 trial has shown promising anti-tumor activity, with early data indicating durable complete responses in some patients. If approved, Actuate may benefit from a Priority Review Voucher, potentially expediting the drug's market entry.
Read more →ACTUActuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
Actuate Therapeutics, Inc. will participate in a webinar hosted by Lantern Pharma regarding the use of AI technology for drug development. The focus will be on their lead investigational drug, elraglusib, which is currently in clinical trials for metastatic pancreatic cancer and Ewing Sarcoma. Experts from both companies will discuss how AI is aiding in the development of biomarkers to assess clinical outcomes. This collaboration signifies a strategic approach to enhancing cancer treatments using advanced technology.
Read more →ACTU2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort
The interim analysis of a safety cohort for a study involving FOLFIRINOX combined with elraglusib and losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC) has been presented at the 2024 AACR conference. This combination therapy aims to improve treatment outcomes for patients with PDAC. Early results indicate a favorable safety profile.
Read more →ACTUTargeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells
The article discusses the targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) to enhance CD8 T-cell reactivity against neuroblastoma cells. However, the text does not provide specific details or results related to this research. It primarily focuses on cookie consent and website functionality, lacking substantive content on the study itself.
Read more →ACTUActuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
Actuate Therapeutics has presented initial data on the combination of elraglusib and FOLFIRINOX at the AACR Special Conference. The early findings indicate promising clinical activity, with three out of six patients showing deep, durable responses. The ongoing Phase 2 trial aims to assess the safety and effectiveness of this new treatment for untreated metastatic pancreatic adenocarcinoma. The study is noted for addressing some critical challenges in treating this difficult cancer.
Read more →ACTUActuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Actuate Therapeutics, Inc. has announced that the FDA granted Orphan Drug Designation for elraglusib, a novel GSK-3β inhibitor, aimed at treating soft tissue sarcomas. This designation is significant as it underscores the therapy's potential to meet urgent medical needs among patients with advanced cancers. Elraglusib has demonstrated positive safety and efficacy profiles in various solid tumors, and its approval supports further development for this challenging cancer type. The Orphan Drug status provides several benefits that could facilitate the drug's development and commercialization.
Read more →ACTUActuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Actuate Therapeutics has reported positive updates regarding elraglusib's performance in its clinical trial for treating relapsed/refractory Ewing Sarcoma. The drug has shown considerable anti-tumor activity, with two patients experiencing ongoing complete responses and a 62% disease control rate. The Phase 1/2 trial is ongoing, and Actuate aims to provide further data in the first half of 2025, seeking to advance elraglusib towards a Phase 2 study. The need for new treatments in this area is underscored by the significant survival challenges faced by patients with this aggressive cancer.
Read more →ACTUA new strategy for adult T-cell leukemia treatment targeting glycogen synthase kinase-3β
The article discusses a new treatment strategy for adult T-cell leukemia that targets glycogen synthase kinase-3β. This approach aims to improve therapeutic outcomes for patients suffering from this aggressive form of leukemia. However, specific details about the strategy's effectiveness or clinical trial results are not provided.
Read more →ACTUActuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Actuate Therapeutics, a biopharmaceutical company focused on challenging cancers, announced its participation at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. During the conference, the company will deliver a corporate presentation on September 10, 2024. Actuate's lead investigational drug, elraglusib, targets key cancer pathways to inhibit tumor growth and boost anti-tumor immunity, positioning the company in a vital sector of oncology treatment.
Read more →ACTUActuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
Actuate Therapeutics, Inc. announced that its President & CEO, Daniel Schmitt, will ring the Nasdaq opening bell on August 23, 2024. This event marks a significant milestone for the company as it celebrates its initial public offering. Schmitt expressed excitement about this new chapter and the support received from investors and team members. The ceremony will be livestreamed from the Nasdaq MarketSite Tower in New York City.
Read more →ACTU▲ +6.3%on this news
Actuate Therapeutics Announces Closing of Initial Public Offering
Actuate Therapeutics, Inc. has announced the closure of its initial public offering, raising $22.4 million through the sale of 2.8 million shares at $8.00 each. The shares began trading on Nasdaq under the symbol ACTU on August 13, 2024. The IPO included an option for underwriters to purchase additional shares to cover over-allotments. Actuate is focused on developing therapies for challenging cancers, with its lead drug, elraglusib, targeting critical molecular pathways involved in tumor growth.
Read more →ACTUActuate Therapeutics Announces Pricing of Initial Public Offering
Actuate Therapeutics, Inc. has announced the pricing of its initial public offering (IPO) at $8.00 per share, with a total expected gross proceeds of $22.4 million. The offering consists of 2,800,000 shares, and underwriters have the option to purchase an additional 420,000 shares. Trading on the Nasdaq Global Market is set to commence on August 13, 2024, with the offering expected to close on August 14, 2024, contingent on customary closing conditions.
Read more →ACTU2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
The article discusses a study presented at the 2024 ASCO conference, which investigates the correlation of therapy-induced neutropenia with survival rates in patients with metastatic pancreatic cancer. The study evaluates the efficacy of the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine and nab-paclitaxel. The findings suggest a potential link between neutropenia and improved patient outcomes.
Read more →ACTU2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
The 2024 ASCO presentation discusses the identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer. This study evaluates the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine and nab-paclitaxel. The findings from the Phase 2 study could lead to improved therapeutic strategies.
Read more →ACTU2024-ASCO-Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study
The 1801 Phase 2 study is investigating the use of elraglusib (9-ING-41) combined with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer. The study aims to analyze cfDNA to identify predictive biomarkers that could enhance treatment outcomes. This research may provide valuable insights into personalized cancer therapy.
Read more →ACTUActuate Therapeutics Files Registration Statement for Initial Public Offering
Actuate Therapeutics, Inc. has filed a registration statement with the SEC for a planned initial public offering of its common stock, with specifics on the number of shares and pricing yet to be determined. The company aims to list on the Nasdaq under the ticker symbol ACTU. Titan Partners Group serves as the book-running manager for the offering. As the registration statement has not yet become effective, the securities cannot be sold until approval is granted.
Read more →ACTUTumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer
The article discusses the use of a tumor microenvironment-modulating oncolytic adenovirus in combination with a GSK-3β inhibitor. This combination aims to enhance the antitumor immune response specifically against bladder cancer. However, the article lacks specific details on results or implications of the findings.
Read more →ACTU2024-AACR-Identification of potential immune biomarkers for GSK-3 inhibitor elraglusib (9-ING-41) in patients with relapsed/refractory metastatic cancer
The article discusses the identification of potential immune biomarkers for the GSK-3 inhibitor elraglusib (9-ING-41) in patients with relapsed/refractory metastatic cancer. However, the content primarily focuses on cookie policies and website functionalities rather than specific details about the study or findings.
Read more →ACTUActuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
Actuate Therapeutics, Inc. has announced two poster presentations at the 2024 AACR Annual Meeting. These presentations will cover significant advancements in research related to elraglusib, their lead drug targeting pancreatic cancer and immune biomarkers. The sessions are scheduled for April 9, 2024, and aim to provide insights into innovative therapies and biomarker identification that could aid in cancer treatment.
Read more →ACTU2024-AACR-Genome wide CRISPR/Cas9 library screening identifies aurora kinase A as a regulator of elraglusib sensitivity in pancreatic cancer
The article discusses a study presented at the 2024 AACR regarding the identification of aurora kinase A as a regulator of elraglusib sensitivity in pancreatic cancer through genome-wide CRISPR/Cas9 library screening. However, the article lacks detailed findings or implications from the study, focusing instead on cookie consent information.
Read more →ACTUGlycogen synthase kinase 3 activity enhances liver inflammation in MASH
The article discusses the role of glycogen synthase kinase 3 (GSK3) in enhancing liver inflammation associated with metabolic-associated steatotic liver disease (MASH). It highlights the potential implications of GSK3 activity on liver health, although specific findings or data are not provided in the text. The article appears to focus on the biochemical mechanisms involved rather than presenting new research results.
Read more →ACTUPhase I Study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies
The article discusses a Phase I study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, which is being tested as a monotherapy or in combination with chemotherapy for patients with advanced malignancies. However, the article does not provide specific details about the study's findings or outcomes.
Read more →ACTUMicrofluidic organoid cultures derived from pancreatic cancer biopsies for personalized testing of chemotherapy and immunotherapy
The article discusses the use of microfluidic organoid cultures derived from pancreatic cancer biopsies. This innovative approach aims to personalize chemotherapy and immunotherapy treatments for patients. However, the article lacks specific details or outcomes related to this method, focusing instead on general cookie consent information.
Read more →ACTUActuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer
Actuate Therapeutics has received Orphan Drug Designation from the FDA for its drug elraglusib, aimed at treating pancreatic cancer, which has a severe unmet medical need with low survival rates. This designation facilitates the drug's development process and interactions with regulatory bodies. Actuate is advancing clinical trials to investigate elraglusib's efficacy in combination with existing chemotherapy treatments for metastatic pancreatic cancer. This highlights the company's commitment to addressing significant challenges in treating this aggressive cancer type.
Read more →ACTUActuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting
Actuate Therapeutics has announced that four presentations will be made at the 2023 ASCO Annual Meeting, showcasing their ongoing research involving elraglusib, a GSK-3 inhibitor. These presentations include studies on patient selection for metastatic melanoma and other cancer types. The meeting will take place from June 2 to 6, 2023, in Chicago, Illinois, emphasizing the importance of Actuate's contributions to cancer treatment advancements. Details regarding the studies will be accessible online following the presentations.
Read more →ACTUActuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting
Actuate Therapeutics announced that it will present three posters at the 2023 AACR Annual Meeting, which takes place from April 14-19, in Orlando, Florida. The presentations will cover various aspects of elraglusib, a GSK-3 inhibitor, including its resistance mechanisms in pancreatic cancer and its immunomodulatory effects as observed in early trials. These contributions underscore Actuate's commitment to advancing cancer treatment through innovative research developments.
Read more →ACTUActuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect
Actuate Therapeutics has announced that Dr. Patricia LoRusso, a member of its Scientific Advisory Board, has been elected President-Elect of the American Association of Cancer Research for 2023-2024. The company congratulated Dr. LoRusso for her significant contributions to cancer research and her role in developing the innovative clinical plans for their lead drug, elraglusib. Dr. LoRusso has been with Actuate's advisory board since 2015 and has held leadership positions in various organizations related to oncology and cancer drug development.
Read more →ACTUActuate Therapeutics Announces Poster Presentations at the 2022 AACR Annual Meeting
CHICAGO and FORT WORTH, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AAC
Read more →ACTUActuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclit
Read more →ACTUActuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib Plus FOLFIRINOX As First Line Therapy for Advanced Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the opening of a randomized study of elraglusib (9-ING-41) plus FOLFIRINOX alone or with Losartan for patients with a
Read more →Competitive Position
How ACTU ranks across every disease it competes inCompetitive Position is a premium feature
See how ACTU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial